An analyst wrote Wednesday that the combination of Lilly's Olumiant and Gilead's Veklury, or remdesivir, could cost nearly $8,000, a high price tag that could potentially hamper uptake, especially given the availability of cheaper drugs like dexamethasone.
The company said it had initiated the Phase III study of Olumiant, one of multiple JAK inhibitors that are being tested to find if they can mitigate the cytokine storm associated with Covid-19's worst complications.
In an interview, Kyan Health Co-Founder and Chief Commercial Officer Konstantin Struck discussed how Kyan gives mid-market and enterprise employers access to premium workforce mental healthcare, at a price point that is affordable.
The Adaptive Covid-19 Treatment Trial will include several investigational therapies for Covid-19, including Lilly's Olumiant, investigated for efficacy against inflammation caused by the disease.